Protein aggregation and its inhibition in biopharmaceutics.
Protein aggregation is arguably the most common and troubling manifestation of protein instability, encountered in almost all stages of protein drug development. Protein aggregation, along with other physical and/or chemical instabilities of proteins, remains to be one of the major road barriers hindering rapid commercialization of potential protein drug candidates. Although a variety of methods have been used/designed to prevent/inhibit protein aggregation, the end results are often unsatisfactory for many proteins. The limited success is partly due to our lack of a clear understanding of the protein aggregation process. This article intends to discuss protein aggregation and its related mechanisms, methods characterizing protein aggregation, factors affecting protein aggregation, and possible venues in aggregation prevention/inhibition in various stages of protein drug development.
Wang
Wei
W
Biotechnology Division, Bayer HealthCare, 800 Dwight Way, Berkeley, CA 94701, USA. wei.2.wang@pfizer.com
D001702:Biopharmaceutics / Q000379:methods*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D011487:Protein Conformation